A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects
A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
San Francisco, California 94110, United States
Pittsburgh, Pennsylvania 15213, United States
Autonoma, Buenos Aires C1119ACN, Argentina
Buenos Aires, Buenos Aires C1280AEB, Argentina
Ciudad de Buenos Aires, Buenos Aires C1121ABE, Argentina
Ciudad de Buenos Aires, Buenos Aires C1181ACH, Argentina
Prov de Santa Fe, Santa Fe Province 2000, Argentina
Westmead Nsw, New South Wales 2145, Australia
Clayton Vic, Victoria 3168, Australia
Parville, Victoria 3050, Australia
Hus, 00029, Finland
Tsuchiura-shi, Ibaraki 300-0053, Japan
Kawasaki-shi, Kanagawa 2138587, Japan
Iruma-gun, Saitama 3500495, Japan
Bunkyo-ku, Tokyo 1138655, Japan
Minato-ku, Tokyo 1058470, Japan
Musashino-shi, Tokyo 1808610, Japan
Distrito Federal, Mexico City 03720, Mexico
Gyeongsangnam-do, 626-770, South Korea
Yunlin, 64041, Taiwan